Abstract
We demonstrate CRISPR-Cas9–mediated correction of a Fah mutation in hepatocytes in a mouse model of the human disease hereditary tyrosinemia. Delivery of components of the CRISPR-Cas9 system by hydrodynamic injection resulted in initial expression of the wild-type Fah protein in ∼1/250 liver cells. Expansion of Fah-positive hepatocytes rescued the body weight loss phenotype. Our study indicates that CRISPR-Cas9–mediated genome editing is possible in adult animals and has potential for correction of human genetic diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
Change history
31 March 2014
In the version of this article initially published online, in the legend for Figure 1d, the scale bars are 100 μm and 20 μm, not “mm.” The error has been corrected for the print, PDF and HTML versions of this article.
References
Cong, L. et al. Science 339, 819–823 (2013).
Hsu, P.D. et al. Nat. Biotechnol. 31, 827–832 (2013).
Mali, P. et al. Science 339, 823–826 (2013).
Cho, S.W., Kim, S., Kim, J.M. & Kim, J.S. Nat. Biotechnol. 31, 230–232 (2013).
Wu, Y. et al. Cell Stem Cell 13, 659–662 (2013).
Schwank, G. et al. Cell Stem Cell 13, 653–658 (2013).
Azuma, H. et al. Nat. Biotechnol. 25, 903–910 (2007).
Paulk, N.K. et al. Hepatology 51, 1200–1208 (2010).
Aponte, J.L. et al. Proc. Natl. Acad. Sci. USA 98, 641–645 (2001).
Liu, F., Song, Y. & Liu, D. Gene Ther. 6, 1258–1266 (1999).
Nielsen, R., Korneliussen, T., Albrechtsen, A., Li, Y. & Wang, J. PLoS ONE 7, e37558 (2012).
Li, H. et al. Nature 475, 217–221 (2011).
Fu, Y. et al. Nat. Biotechnol. 31, 822–826 (2013).
Ran, F.A. et al. Cell 154, 1380–1389 (2013).
Kanasty, R., Dorkin, J.R., Vegas, A. & Anderson, D. Nat. Mater. 12, 967–977 (2013).
Acknowledgements
We thank I. Zhuang and W. Cai for technical assistance, F. Zhang for sharing pX330 CRISPR vectors, and D. Crowley and K. Cormier for histology. This work was supported in part by grants 2-PO1-CA42063 to P.A.S. and T.J. and core grant P30-CA14051 from the National Cancer Institute. This work was supported in part by National Institutes of Health (NIH) Grant R01-CA133404 and the Marie-D. & Pierre Casimir-Lambert Fund to P.A.S. T.J. is a Howard Hughes Investigator, the David H. Koch Professor of Biology and a Daniel K. Ludwig Scholar. H.Y. and S.C. are supported by 5-U54-CA151884-04 NIH Centers for Cancer Nanotechnology Excellence and the Harvard-MIT Center of Cancer Nanotechnology Excellence. W.X. is supported by grant 1K99CA169512. S.C. is a Damon Runyon Fellow (DRG-2117-12). The authors acknowledge the service of the late Sean Collier to the MIT community. We thank the Swanson Biotechnology Center for technical support.
Author information
Authors and Affiliations
Contributions
H.Y., W.X. and D.G.A. designed the study. H.Y., W.X., S.C., R.L.B. and E.B. performed experiments and analyzed data. M.G., V.K. and P.A.S. provided reagents and conceptual advice. H.Y., W.X., T.J. and D.G.A. wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
D.G.A., H.Y., R.L.B., T.J. and W.X. have applied for patents on the subject matter of this paper.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–8, Supplementary Discussion, Supplementary Methods and Supplementary Tables 1 and 2 (PDF 1521 kb)
Supplementary Table 3
Next-generation sequencing data for FAH2 treated mice. (XLSX 692 kb)
Supplementary Table 4
Next-generation sequencing data for off-target analysis of FAH2. (XLSX 47 kb)
Rights and permissions
About this article
Cite this article
Yin, H., Xue, W., Chen, S. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32, 551–553 (2014). https://doi.org/10.1038/nbt.2884
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2884
This article is cited by
-
Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation
Molecular Cancer (2023)
-
Doxycycline-dependent Cas9-expressing pig resources for conditional in vivo gene nullification and activation
Genome Biology (2023)
-
A potential paradigm in CRISPR/Cas systems delivery: at the crossroad of microalgal gene editing and algal-mediated nanoparticles
Journal of Nanobiotechnology (2023)
-
CATI: an efficient gene integration method for rodent and primate embryos by MMEJ suppression
Genome Biology (2023)
-
The applications of CRISPR/Cas-mediated genome editing in genetic hearing loss
Cell & Bioscience (2023)